BIOCYTOGEN-B (02315) has surged more than 5% once again. At the time of writing, the stock was up 5.41%, trading at HK$47.96, with a turnover of HK$69.8685 million. The movement follows the company's recent release of its 2025 performance forecast, projecting annual revenue to reach approximately RMB 1.369 billion to RMB 1.389 billion. This represents an increase of RMB 389 million to RMB 408 million compared to the previous year, a year-on-year growth of 39.61% to 41.65%. The company also expects attributable net profit to be in the range of RMB 162 million to RMB 182 million, an increase of RMB 129 million to RMB 149 million from the prior year, indicating a substantial surge of 384.26% to 443.88%.

Guolian Minsheng Securities attributes this high revenue growth to the robust performance of the innovative animal model and preclinical CRO businesses. The institution noted that since 2025, the company has entered into out-licensing agreements with several leading domestic and international pharmaceutical firms, and multiple pipelines have received IND approvals. As these licensed pipelines advance, the company is anticipated to secure milestone payments and other revenues, further elevating its growth potential.